2022
Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness
Lin C, Gou M, Pan S, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Luo X, Li CR, Zhang P, Huang J, Hong L, Tan Y. Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness. Neuroscience Letters 2022, 788: 136826. PMID: 35944595, DOI: 10.1016/j.neulet.2022.136826.Peer-Reviewed Original ResearchConceptsBrain cortical thicknessCognitive impairmentCognitive deficitsGray matter thicknessSchizophrenia (MATRICS) Consensus Cognitive BatteryAttention/vigilanceConsensus Cognitive BatteryCortical thicknessSerum Hcy levelsFirst-episode patientsHealthy controlsHigh homocysteineWorking memoryHcy levelsCognitive batteryNegative Symptom ScaleCognitive functionTreatment researchHigh-resolution magnetic resonance imagingSymptom ScaleSandwich enzyme-linked immunosorbentSchizophreniaHigher cortical thicknessImpairmentEnzyme-linked immunosorbent
2020
Psychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder
Liang S, Yu W, Ma X, Luo S, Zhang J, Sun X, Luo X, Zhang Y. Psychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder. Journal Of Affective Disorders 2020, 265: 132-138. PMID: 32090734, DOI: 10.1016/j.jad.2020.01.052.Peer-Reviewed Original ResearchConceptsMajor depression disorderMATRICS Consensus Cognitive BatteryMDD patientsCognitive impairmentChinese patientsConsensus Cognitive BatteryBipolar disorderHamilton Depression Rating Scale-17Cognitive AssessmentChinese MDD patientsMajor depressive disorderSeverity of symptomsMontreal Cognitive AssessmentConcurrent validityMild cognitive impairmentCognitive batteryPsychometric propertiesGood concurrent validityMedication treatmentDepressive disorderHealthy controlsGood internal consistencyDepressive symptomsDepression disorderPatients
2019
Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia
Xie T, Li Q, Luo X, Tian L, Wang Z, Tan S, Chen S, Yang G, An H, Yang F, Tan Y. Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia. Cognitive Neurodynamics 2019, 13: 357-365. PMID: 31354881, PMCID: PMC6624222, DOI: 10.1007/s11571-019-09530-3.Peer-Reviewed Original ResearchAttention/vigilanceSpeed of processingTotal antioxidant statusFirst-episode drug-naïve patientsDrug-naïve patientsCognitive impairmentCognitive deficitsSchizophrenia (MATRICS) Consensus Cognitive BatteryMCCB total scoreConsensus Cognitive BatteryHealthy controlsAntioxidant statusPlasma total antioxidant statusSex-matched healthy controlsOxidative stressPlasma TAS levelsPathophysiology of schizophreniaCognitive batteryStroop testNegative Syndrome ScaleReactive oxygen species-induced oxidative damageTreatment researchPsychopathological symptomsFEDN patientsHealthy subjects